Condition
Psychotic Disorder NOS
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 42/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results67% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 4 (2)
Trial Status
Completed2
Terminated1
Unknown1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT01321177Not ApplicableCompleted
An Integrated Program for the Treatment of First Episode of Psychosis
NCT01888627Not ApplicableUnknown
Integrated Care in Psychotic Disorders With Severe Mental Illness
NCT02949232Phase 4Terminated
Prednisolone Addition for Patients With Recent-onset Psychotic Disorder
NCT01339858Phase 4Completed
The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia
Showing all 4 trials